Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
March 22, 2019 06:48 ET
|
Genmab A/S
Company Announcement Type II variation application submitted to the EMA for daratumumab in combination with lenalidomide and dexamethasone as treatment for newly diagnosed multiple myeloma patients...
Genmab Announces Appointment of Marisol Peron as Head of Communications and Investor Relations
March 11, 2019 04:12 ET
|
Genmab A/S
Media ReleaseCopenhagen, Denmark, March 11, 2019 Genmab A/S (Nasdaq Copenhagen: GEN) announced today that Marisol Peron has been appointed Corporate Vice President, Communications and Investor...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
March 01, 2019 13:32 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; March 1, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 6,397 restricted stock units and...
Genmab A/S Summons Annual General Meeting
February 28, 2019 01:58 ET
|
Genmab A/S
Company Announcement Genmab A/S to hold Annual General Meeting on March 29, 2019 Copenhagen, Denmark; Thursday, February 28, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) summons the Annual General...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
February 26, 2019 12:43 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; February 26, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 26,297 shares as a consequence of the exercise of employee...
Genmab Announces Positive Topline Results in Phase III COLUMBA Study of Subcutaneous Daratumumab
February 25, 2019 11:47 ET
|
Genmab A/S
Company Announcement Phase III COLUMBA study comparing the subcutaneous formulation of daratumumab to the intravenous formulation in patients with relapsed or refractory multiple myeloma met both...
Genmab 2018 Annual Report
February 20, 2019 11:18 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; February 20, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today its Annual Report for 2018. Below is a summary of business progress and...
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) Split Dosing Regimen
February 12, 2019 01:07 ET
|
Genmab A/S
Media Release Copenhagen, Denmark, February 12, 2019 DARZALEX split dosing regimen approved by U.S. FDAProvides healthcare professionals with option to split first DARZALEX infusion over two...
Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
January 31, 2019 11:36 ET
|
Genmab A/S
Company Announcement Genmab, Janssen and MorphoSys have agreed to end the patent infringement lawsuit launched by MorphoSys AG relating to DARZALEXOn January 25, 2019, a summary judgement decision...
Genmab Announces that the patents asserted against DARZALEX® in the United States have been declared invalid by summary judgment.
January 26, 2019 09:14 ET
|
Genmab A/S
Company Announcement Patents asserted against Janssen Biotech, Inc. & Genmab in the United States have been declared invalid by summary judgment Copenhagen, Denmark; January 26, 2019 – Genmab...